Celltrion

Main menu

Capacity

Driving ahead in the global market with know-how accumulated over many years and outstanding technological prowess

Technological Prowess

Development of ‘Remsima,’ the first antibody biosimilar in the world
Possession of major cell lines necessary for developing biosimilars
Possession of various core technologies necessary for developing novel pharmaceuticals

Response Capacity for Global Licensing

Approval of Remsima by the sales approval institutions of approximately 80 countries around the world
Possession of specialized knowledge and experience in product licensing process and global regulation standards
Implementation of global clinical tests with the first approval of the clinical tests application in EU countries

Global Marketing and Distribution Network

Completion of strategic global sales network to launch products with multinational pharmaceutical companies that have constructed global distribution networks

Production Capacity

cGMP biologics production equipment approved by FDA
Quality control system and technology for producing biologics at an international level
Verification of production capacity through CMO activities with global pharmaceutical companies for many years

위로 가기